We are live on ! Find out more
XLO icon

Xilio Therapeutics

9.00 USD
-0.01
0.11%
At close Updated Aug 28, 4:00 PM EDT
1 day
-0.11%
5 days
-3.43%
1 month
-1.64%
3 months
5.63%
6 months
18.89%
Year to date
-4.26%
1 year
-6.93%
5 years
-95.98%
10 years
-95.98%
 

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Employees: 76

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
17 days ago
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2026.
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Neutral
GlobeNewsWire
1 month ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Positive
Zacks Investment Research
3 months ago
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Cancer Stocks That Are Advancing the Future of Oncology Care
Neutral
Zacks Investment Research
3 months ago
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Neutral
GlobeNewsWire
3 months ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
4 months ago
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Neutral
GlobeNewsWire
4 months ago
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
Neutral
GlobeNewsWire
4 months ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price charts implemented using Lightweight Charts™